Fiore T, Chapman S, Perry K, Stenzel M, Gormley J, Cu-Uvin S; International Conference on AIDS.
Int Conf AIDS. 2000 Jul 9-14; 13: abstract no. MoPeB2241.
T. Fiore, The Miriam Hospital, 164 Summit Ave., Providence, Rhode Island, United States, Tel.: +1 401 793 40 40, Fax: +1 401 273 02 85, E-mail: tfiore@lifespan.org
Objective: To determine the prevalence of cervical dysplasia among HIV positive women on haart, non-haart and no antiretroviral therapy. Methods: Cross sectional study of PAP Smear results on 90 HIV seropositive women at the Miriam Hospital Immunology Center. Cervical dysplasia is defined as Atypical Squamous Cells of Uncertain Significance (ASCUS), Low Grade Squamous Intraepithelial Lesion (LGSIL), high grade sil. Haart is defined as combination therapy with a PI or NNRTI. Non-Haart regimens are defined as dual Nrti therapy. PAP Smear results were correlated with antiretroviral therapy, CD4 counts and PVL. CD4 counts and PVLS were done within three months of PAP Smear. Results: Demographics: Mean age 39 years. Race: Caucasian 41%, African-American 35%, Latina 23%, Other 1%. Risk factors: HTX 49%, IDU 51%. Mean CD4 463. Mean plasma viral load 29,319 copies per ml. 60% (54/90) on haart. 13% (12/90) Non-haart. 27%(24/90) No therapy. 66% (59/90) had PAP Smears WNL. 34% (31/90) had cervical dysplasia. Of these 31 women 6% (2/31) had HGSIL, 49% (15/31) had LGSIL, and 45%(14/31) had ASCUS. Among women on haart, non-haart, and no therapy, 31%, 42%, 33% respectively had cervical dysplasia. Among women with CD4 counts >200, 200-500, >500, 42%, 41%, 24% respectively had cervical dysplasia. Among women with PVLS >400, 400-10,000, and >100,000 copies per ml, 24%, 42%, and 40% respectively had cervical dysplasia. Conclusions: The prevalence of cervical dysplasia among 90 women in our immunology center does not seem to be altered by the intensity of antiretroviral regime. In this study, low rates of cervical dysplasia are associated with preserved CD4 counts and viral suppression.
Publication Types:
Keywords:
- Antiretroviral Therapy, Highly Active
- CD4 Lymphocyte Count
- Carcinoma in Situ
- Cervical Intraepithelial Neoplasia
- Cross-Sectional Studies
- Female
- HIV Seropositivity
- Humans
- Prevalence
- Risk Factors
- Uterine Cervical Dysplasia
- Vaginal Smears
- Viral Load
- epidemiology
Other ID:
UI: 102237841
From Meeting Abstracts